Valoctocogene Roxaparvovec-rvox (Roctavian) — CPB 1037 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 1037 for valoctocogene roxaparvovec-rvox (Roctavian), effective September 26, 2025. Billing teams need to confirm precertification workflows, GCIT Network site-of-care requirements, and companion diagnostic lab code billing before submitting claims.

Aetna's Roctavian coverage policy update touches J1412 — the HCPCS code for valoctocogene roxaparvovec-rvox injection — along with 21 companion CPT codes covering liver function labs, coagulation panels, and infusion administration. This is one of the highest-dollar gene therapy policies Aetna manages, and a single documentation gap means a claim denial on a therapy that can exceed $2.9 million per patient. The CPB 1037 Aetna system update also clarifies the GCIT Network requirement, which now sits at the center of your site-of-care strategy for this drug.

Quick-Reference Table

Aetna Roctavian Coverage Criteria and Medical Necessity Requirements 2025

The Aetna Roctavian coverage policy applies to commercial medical plans only. Medicare members follow separate criteria — check Aetna's Medicare Part B step therapy page, not this CPB.

Precertification is mandatory. There are no exceptions for participating providers. Call (866) 752-7021 or fax the Statement of Medical Necessity form to (888) 267-3277 before any administration occurs. If you skip this step, you don't have a coverage question — you have a denial.

The medical necessity review for Roctavian is built around the AAV5 Detect CDX companion diagnostic workup. That workup includes a specific panel of lab tests Aetna expects to see documented before and around the gene therapy administration. The lab codes grouped under "AAV5 Detect CDX – no specific code" in CPB 1037 include CPT 82247 and 82248 (bilirubin, total and direct), CPT 84450 and 84460 (AST and ALT liver enzymes), CPT 82977 (GGT), CPT 84075 (alkaline phosphatase), CPT 82565 and 82570 (creatinine), CPT 85240 (Factor VIII, 1-stage), CPT 85335 (factor inhibitor test), CPT 85610 (prothrombin time), CPT 85730 and 85732 (PTT), CPT 85049 (platelet count), CPT 88720 (transcutaneous bilirubin), CPT 91200 (liver elastography), and CPT 76705 (abdominal ultrasound, limited). These aren't optional add-ons. They're the documented baseline Aetna uses to assess medical necessity for a therapy this expensive.

Prior authorization requirements extend to the site of care itself. Unless a member's plan has opted out, Roctavian must be administered at an Aetna Institutes® Gene Based, Cellular and Other Innovative Therapy (GCIT®) Network site. Administering at a non-designated facility — even an academic medical center — can void coverage entirely. Check the GCIT Designated Networks list before scheduling.

Whether Roctavian reimbursement is worth pursuing depends heavily on your program's ability to meet all three requirements simultaneously: prior authorization approval, GCIT Network designation, and complete companion diagnostic documentation. Miss any one of these and you're looking at a full denial.

Aetna Roctavian Exclusions and Non-Covered Indications

CPB 1037 is written for hereditary Factor VIII deficiency (ICD-10 D66) — hemophilia A. Roctavian has no established coverage pathway under this policy for acquired hemophilia, von Willebrand disease, or other coagulation disorders.

The related Factor VIII HCPCS codes listed in CPB 1037 — J7182, J7185, J7186, J7188, J7190, J7191, J7192, J7204, J7205, J7207, J7208, J7209, J7210, and J7211 — are classified as "Other HCPCS codes related to the CPB." These are not covered under the same pathway as J1412. They represent conventional Factor VIII replacement products that may be part of the patient's prior treatment history or bridge therapy. Billing them as substitutes for J1412 won't work, and billing J1412 alongside them without clear clinical differentiation in the record will invite scrutiny.

ICD-10 codes spanning infectious diseases (A00.0–B99.9) and neoplasms (C00.0–D49.9) appear in the code table. These are likely included to capture contraindications or comorbidity screening requirements — not as covered treatment indications for Roctavian. Don't use them as primary diagnosis codes on a Roctavian claim.

Coverage Indications at a Glance

Aetna Roctavian Billing Guidelines and Action Items 2025

These are the steps your billing team and infusion program need to complete now. The effective date is September 26, 2025 — if you're treating hemophilia A patients who might be candidates, you should already be working through this list.

If you're not sure how CPB 1037 applies to your specific patient population or facility setup, loop in your compliance officer before the September 26, 2025 effective date. The financial exposure on a mishandled Roctavian claim is not a problem you want to discover after infusion.

CPT, HCPCS, and ICD-10 Codes for Valoctocogene Roxaparvovec-rvox Under CPB 1037

Covered HCPCS Codes (When Selection Criteria Are Met)

Companion Diagnostic CPT Codes (AAV5 Detect CDX — No Specific CDx Code Assigned)

Key ICD-10-CM Diagnosis Codes